You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 294 No. 9, September 7, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (34)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Similar articles in JAMA
 Topic Collections
 •Medical Practice
 •Conflict of Interest
 •Medical Education
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Medical Students’ Exposure to and Attitudes About Drug Company Interactions

A National Survey

Frederick S. Sierles, MD; Amy C. Brodkey, MD; Lynn M. Cleary, MD; Frederick A. McCurdy, MD, PhD, MBA; Matthew Mintz, MD; Julia Frank, MD; D. Joanne Lynn, MD; Jason Chao, MD; Bruce Z. Morgenstern, MD; William Shore, MD; John L. Woodard, PhD

JAMA. 2005;294:1034-1042.

Context  While exposure to and attitudes about drug company interactions among residents have been studied extensively, relatively little is known about relationships between drug companies and medical students.

Objective  To measure third-year medical students’ exposure to and attitudes about drug company interactions.

Design, Setting, and Participants  In 2003, we distributed a 64-item anonymous survey to 1143 third-year students at 8 US medical schools, exploring their exposure and response to drug company interactions. The schools’ characteristics included a wide spectrum of ownership types, National Institutes of Health funding, and geographic locations. In 2005, we conducted a national survey of student affairs deans to measure the prevalence of school-wide policies on drug company–medical student interactions.

Main Outcome Measures  Monthly frequency of students’ exposure to various activities and gifts during clerkships, and attitudes about receiving gifts.

Results  Overall response rate was 826/1143 (72.3%), with range among schools of 30.9%-90.7%. Mean exposure for each student was 1 gift or sponsored activity per week. Of respondents, 762/818 (93.2%) were asked or required by a physician to attend at least 1 sponsored lunch. Regarding attitudes, 556/808 (68.8%) believed gifts would not influence their practices and 464/804 (57.7%) believed gifts would not affect colleagues’ practices. Of the students, 553/604 (80.3%) believed that they were entitled to gifts. Of 183 students who thought a gift valued at less than $50 was inappropriate, 158 (86.3%) had accepted one. The number of students who simultaneously believed that sponsored grand rounds are educationally helpful and are likely to be biased was 452/758 (59.6%). Students at 1 school who had attended a seminar about drug company–physician relationships were no more likely than the nonattending classmates to show skepticism. Of the respondents, 704/822 (85.6%) did not know if their school had a policy on these relationships. In a national survey of student affairs deans, among the 99 who knew their policy status, only 10 (10.1%) reported having school-wide policies about these interactions.

Conclusions  Student experiences and attitudes suggest that as a group they are at risk for unrecognized influence by marketing efforts. Research should focus on evaluating methods to limit these experiences and affect the development of students’ attitudes to ensure that physicians’ decisions are based solely on helping each patient achieve the greatest possible benefit.


Author Affiliations: Departments of Psychiatry and Behavioral Sciences (Drs Sierles and Woodard) and Psychology (Dr Woodard), Rosalind Franklin University of Medicine and Science, North Chicago, Ill; Department of Psychiatry, University of Pennsylvania, Philadelphia (Dr Brodkey); Office of the Associate Dean, and Department of Internal Medicine, State University at New York Upstate Medical University, Syracuse (Dr Cleary); Department of Pediatrics, University of Nebraska School of Medicine, Omaha (Dr McCurdy); Departments of Internal Medicine (Dr Mintz) and Psychiatry (Dr Frank), George Washington University, Washington, DC; Department of Neurology, Ohio State University, Columbus (Dr Lynn); Department of Family Medicine, Case Western Reserve University, Cleveland, Ohio (Dr Chao); Department of Pediatrics, Mayo Clinic College of Medicine, Rochester, Minn (Dr Morgenstern); and Department of Family and Community Medicine, University of California, San Francisco (Dr Shore). Dr McCurdy is now Regional Chairman of Pediatrics, Texas Tech University, Amarillo.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTERS

Medical Student Exposure to Drug Company Interactions
Michael Eisman
JAMA. 2006;295(3):281.
EXTRACT | FULL TEXT  

Medical Student Exposure to Drug Company Interactions—Reply
Frederick S. Sierles
JAMA. 2006;295(3):281-282.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmaceutical industry financial support for medical education: benefit, or undue influence?
Brody
J Law Med Ethics 2009;37:451-460.
 

Effect of Exposure to Small Pharmaceutical Promotional Items on Treatment Preferences
Grande et al.
Arch Intern Med 2009;169:887-893.
ABSTRACT | FULL TEXT  

Teaching the next generation of neurologists
Elkind
Neurology 2009;72:657-663.
ABSTRACT | FULL TEXT  

Exposing Nursing Students To the Marketing Methods of Pharmaceutical Companies
Civaner et al.
Nurs Ethics 2008;15:396-410.
ABSTRACT  

To What Extent Do Educational Interventions Impact Medical Trainees' Attitudes and Behaviors Regarding Industry-Trainee and Industry-Physician Relationships?
Carroll et al.
Pediatrics 2007;120:e1528-e1535.
ABSTRACT | FULL TEXT  

Virtues-Based Advice for Beginning Medical Students
Coverdale
Acad. Psychiatry 2007;31:354-357.
ABSTRACT | FULL TEXT  

Experience of VA Psychiatrists With Pharmaceutical Detailing of Antipsychotic Medications
Sernyak and Rosenheck
Psychiatr. Serv. 2007;58:1292-1296.
ABSTRACT | FULL TEXT  

Pharmacy residents' attitudes toward pharmaceutical industry promotion
Ashker and Burkiewicz
Am J Health Syst Pharm 2007;64:1724-1731.
ABSTRACT | FULL TEXT  

Medical Education and the Pharmaceutical Industry: A Review of Ethical Guidelines and Their Implications for Psychiatric Training
Geppert
Acad. Psychiatry 2007;31:32-39.
ABSTRACT | FULL TEXT  

Medical Education and the Pharmaceutical Industry: Managing an Uneasy Alliance
Jibson
Acad. Psychiatry 2006;30:36-39.
FULL TEXT  

The Role of the Pharmaceutical Industry in Medical Education in Psychiatry
Lazarus
Acad. Psychiatry 2006;30:40-44.
FULL TEXT  

Medical Student Exposure to Drug Company Interactions
Eisman
JAMA 2006;295:281-281.
FULL TEXT  

The Price of Free Samples
Dubik
AAP Grand Rounds 2005;14:51-52.
FULL TEXT  

Medical Education 2005: From Allegory to Bull Moose
Golub
JAMA 2005;294:1108-1110.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.